دورية أكاديمية
Effect of oral tetracycline on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia / a single-centre randomized controlled isotope study.
| العنوان: | Effect of oral tetracycline on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia / a single-centre randomized controlled isotope study. |
|---|---|
| المؤلفون: | Potgieter MA; Farmovs-Parexel, Bloemfontein, South Africa. Linda.Potgieter@PAREXEL.com, Potgieter JH, Venter C, Venter JL, Geisser P |
| المصدر: | Arzneimittel-Forschung [Arzneimittelforschung] 2007; Vol. 57 (6A), pp. 376-84. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Editio Cantor Country of Publication: Germany NLM ID: 0372660 Publication Model: Print Cited Medium: Print ISSN: 0004-4172 (Print) Linking ISSN: 00044172 NLM ISO Abbreviation: Arzneimittelforschung Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Aulendorf, Editio Cantor |
| مواضيع طبية MeSH: | Anemia, Iron-Deficiency/*metabolism , Anti-Bacterial Agents/*pharmacokinetics , Ferric Compounds/*pharmacokinetics , Iron/*pharmacokinetics , Tetracycline/*pharmacokinetics, Adult ; Anemia, Iron-Deficiency/drug therapy ; Anti-Bacterial Agents/blood ; Chemical Phenomena ; Chemistry, Physical ; Cross-Over Studies ; Dietary Supplements ; Drug Interactions ; Erythrocyte Indices ; Erythrocytes/metabolism ; Female ; Ferric Compounds/blood ; Ferric Compounds/therapeutic use ; Ferritins/blood ; Hemoglobins/metabolism ; Humans ; Iron/blood ; Iron Chelating Agents/pharmacology ; Iron Radioisotopes/pharmacokinetics ; Male ; Middle Aged ; Prospective Studies ; Quality Control ; Sample Size ; Single-Blind Method ; Tetracycline/blood |
| مستخلص: | The study was carried out as an open-label, laboratory-blind, single-dose, randomized, two-period crossover, isotope efficacy study. Twenty-two patients with iron-deficiency anemia were enrolled in the study. The study consisted of two treatment phases of 15 days each, including blood sample measurements for Fe-59 activity. The two treatments were given orally. Treatment A was Fe-59 labeled iron(III)-hydroxide polymaltose complex (IPC, Maltofer) equivalent to 100 mg elemental iron given orally. Treatment B consisted of Fe-59 labeled IPC complex equivalent to 100 mg elemental iron and 500 mg tetracycline HCl (CAS 64-75-5) given orally. No differences between the two treatment groups with regard to the erythrocyte iron uptake were found, and thus IPC can be used with tetracycline, if necessary. |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Ferric Compounds) 0 (Hemoglobins) 0 (Iron Chelating Agents) 0 (Iron Radioisotopes) 2UA751211N (ferric hydroxide) 9007-73-2 (Ferritins) E1UOL152H7 (Iron) F8VB5M810T (Tetracycline) UM5219H89V (teferrol) |
| تواريخ الأحداث: | Date Created: 20070819 Date Completed: 20070911 Latest Revision: 20161124 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1055/s-0031-1296686 |
| PMID: | 17691587 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0004-4172 |
|---|---|
| DOI: | 10.1055/s-0031-1296686 |